Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492474 | 1.00 | USP2 (0.44) | USP2SMN1; SMN2CTSKCTSSCTSL | |
| SCHEMBL16435378 | 0.92 | CTSK (0.48) | USP2SMN1; SMN2CTSKCTSSCTSL | |
| SCHEMBL6423547 | 0.86 | TSHR (0.38) | CTSKCTSSCTSLCTSBTSHR | |
| SCHEMBL16435346 | 0.83 | CTSS (0.45) | CTSKCTSSCTSLCTSBTSHR | |
| SCHEMBL18058298 | 0.82 | CTSK (0.44) | USP2SMN1; SMN2CTSKCTSSCTSL | |
| SCHEMBL8235945 | 0.82 | SYK (0.59) | CTSKCTSSCTSLCTSB | |
| SCHEMBL14850864 | 0.80 | ITGB3 (0.46) | CTSKCTSSCTSLCTSBTSHR | |
| SCHEMBL25177957 | 0.80 | CTSK (0.48) | USP2SMN1; SMN2CTSKCTSSCTSL | |
| SCHEMBL14850788 | 0.79 | ITGB3 (0.45) | CTSKCTSSCTSLCTSBTSHR | |
| SCHEMBL10076126 | 0.79 | CTSK (0.50) | USP2SMN1; SMN2CTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | USP2 3772/4885SMN1; SMN2 4730/4885CTSK 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.